Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves brivaracetam for partial onset epilepsy

The US Food and Drug Administration (FDA) has approved brivaracetam (Briviact) as an add-on treatment for partial onset seizures in patients with epilepsy who are over 16 years of age.

The drug, which is indicated to treat seizures that start in a limited area of the brain, has been made available on the outcome of three clinical trials.

The trials involved 1,550 patients and confirmed that brivaracetam, when taken with other medications, was capable of reducing the number of seizures. The most common side effects included drowsiness, dizziness, fatigue, nausea and vomiting.

“Patients can have different responses to the various seizure medicines that are available,” says Billy Dunn, director of the division of neurology products in the FDA’s Center for Drug Evaluation and Research. “I am pleased that patients with epilepsy have a new treatment option.”

The FDA reiterates that a medicines guide for patients must be given when the drug is dispensed.

“As is true for all drugs that treat epilepsy, the most serious risks include thoughts about suicide, attempts to commit suicide, feelings of agitation, new or worsening depression, aggression and panic attacks,” the FDA says. “Rarely, patients may exhibit an allergic reaction associated with swelling of the lips, eyelids, or tongue with or without difficulty breathing.”

In Europe, brivaracetam was granted a marketing authorisation for the same indication in January 2016 but is subject to additional monitoring. The drug is marketed in the UK and the United States by UCB Pharma Ltd.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200743

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Food and Drug Administration (FDA) Building 51 Center for Drug Evaluation and Research

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.